- Home
- CLGN vs DRRX Comparison
CLGN vs DRRX Comparison
Compare CLGN & DRRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLGN
- DRRX
- Stock Information
- Founded
- CLGN 2004
- DRRX 1998
- Country
- CLGN Israel
- DRRX United States
- Employees
- CLGN N/A
- DRRX N/A
- Industry
- CLGN Industrial Specialties
- DRRX Biotechnology: Pharmaceutical Preparations
- Sector
- CLGN Health Care
- DRRX Health Care
- Exchange
- CLGN Nasdaq
- DRRX Nasdaq
- Market Cap
- CLGN 51.3M
- DRRX 44.4M
- IPO Year
- CLGN N/A
- DRRX 2000
- Fundamental
- Price
- CLGN $3.77
- DRRX $0.85
- Analyst Decision
- CLGN Strong Buy
- DRRX Buy
- Analyst Count
- CLGN 2
- DRRX 2
- Target Price
- CLGN $12.50
- DRRX $5.00
- AVG Volume (30 Days)
- CLGN 13.5K
- DRRX 124.7K
- Earning Date
- CLGN 11-27-2024
- DRRX 11-13-2024
- Dividend Yield
- CLGN N/A
- DRRX N/A
- EPS Growth
- CLGN N/A
- DRRX N/A
- EPS
- CLGN N/A
- DRRX N/A
- Revenue
- CLGN $650,000.00
- DRRX $8,594,000.00
- Revenue This Year
- CLGN N/A
- DRRX $54.32
- Revenue Next Year
- CLGN $692.59
- DRRX N/A
- P/E Ratio
- CLGN N/A
- DRRX N/A
- Revenue Growth
- CLGN N/A
- DRRX N/A
- 52 Week Low
- CLGN $3.31
- DRRX $0.48
- 52 Week High
- CLGN $6.99
- DRRX $1.88
- Technical
- Relative Strength Index (RSI)
- CLGN 34.26
- DRRX 42.97
- Support Level
- CLGN $3.60
- DRRX $0.72
- Resistance Level
- CLGN $4.17
- DRRX $0.83
- Average True Range (ATR)
- CLGN 0.19
- DRRX 0.08
- MACD
- CLGN -0.05
- DRRX 0.02
- Stochastic Oscillator
- CLGN 2.26
- DRRX 52.40
About CLGN CollPlant Biotechnologies Ltd
CollPlant Biotechnologies Ltd is a regenerative and aesthetic medicine company focused on 3D bioprinting of tissues and organs and medical aesthetics. Its products are based on its rhCollagen (recombinant human collagen) produced with CollPlant's proprietary plant based genetic engineering technology. These products address indications for the diverse fields of tissue repair, aesthetics, and organ manufacturing. The revenues include income from business collaborators and sales of the BioInk product for the development of 3D bioprinting of organs and tissues, sales of rhCollagen for the medical aesthetics market, and sales in Europe of the products for tendinopathy and wound healing. The company operates in United States, which derives key revenue, Canada, Europe and Other, and Israel.
About DRRX DURECT Corporation
Durect Corp is a biopharmaceutical company. It is engaged in the research, development, and manufacturing of pharmaceutical products. The company develops pharmaceutical products based on two categories which include new chemical entities and proprietary pharmaceutical programs. The company's pipeline products consist of DUR-928, POSIMIR, and others. Geographically, the company operates in the United States, Europe, Japan, and other countries, of which key revenue is derived from the Europe .